Introduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam that is approved for the treatment of pediatric (≥ 3 months) and adult patients with complicated infections including hospital-acquired and ventilator-associated pneumonia (HAP/VAP), and bacteremia. This systematic literature review and meta-analysis (PROSPERO registration: CRD42022362856) aimed to provide a quantitative and qualitative synthesis to evaluate the effectiveness of CAZ-AVI in treating adult patients with bacteremia or nosocomial pneumonia caused by carbapenem-resistant Enterobacterales (non metallo-β-lactamase-producing strains) and multi-drug resistant (MDR) Pseudomonas aeruginosa infections.
Methods: The databases included in the search, until November 7, 2022, were Embase and PubMed. A total of 24 studies (retrospective: 22, prospective: 2) with separate outcomes for patients with bacteremia or pneumonia were included.
Results: The outcomes assessed were all-cause mortality, clinical cure, and microbiological cure. Qualitative (24 studies) and quantitative (8/24 studies) syntheses were performed. The quality of the studies was assessed using the MINORS checklist and the overall risk of bias was moderate to high.
Conclusions: In studies included in the meta-analysis, lower all-cause mortality for patients with bacteremia (OR = 0.30, 95% CI 0.19-0.46) and improved rates of clinical cure for patients with bacteremia (OR = 4.90, 95% CI 2.60-9.23) and nosocomial pneumonia (OR = 3.20, 95% CI 1.55-6.60) was observed in the CAZ-AVI group compared with the comparator group. Data provided here may be considered while using CAZ-AVI for the treatment of patients with difficult-to-treat infections.
Systematic Review Registration: PROSPERO CRD42022362856.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219669 | PMC |
| http://dx.doi.org/10.1007/s40121-024-00999-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors of acute kidney injury, septic shock and acute respiratory distress syndrome in patients with blood culture‑positive sepsis.
Exp Ther Med
February 2025
Department of Infectious Diseases, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000, P.R. China.
Sepsis, a condition characterized by a dysregulated host response to infection, can progress to septic shock and lead to various complications. The present study aimed to identify risk factors for the early clinical identification of sepsis patients at heightened risk of complications. In the present study, a total of 383 hospitalized patients with sepsis and positive blood cultures were enrolled.
View Article and Find Full Text PDFMetronidazole-Associated Peripheral Neuropathy in a Patient With End-Stage Renal Failure.
Cureus
December 2024
Internal Medicine, Eastern Virginia Medical School, Norfolk, USA.
Metronidazole is a broad-spectrum antimicrobial that is associated with 0.16% 100-day incidence rates for peripheral neuropathy. In this report, we present an interesting and rare presentation of peripheral neuropathy secondary to metronidazole use for bacteremia and sepsis in a patient with end-stage renal failure.
View Article and Find Full Text PDFClinical characteristics and antimicrobial susceptibility of infection over a 5-year trend at a university hospital in Japan.
Nagoya J Med Sci
November 2024
Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan.
() is known to cause intra-abdominal and anaerobic bloodstream infections. However, clinical insights and information on antimicrobial susceptibility in infections are limited. This study aimed to elucidate the clinical characteristics and antimicrobial susceptibility of infections.
View Article and Find Full Text PDFRisk Factors for Infection-Attributable Mortality in Patients With Bacteremia: A Competing Risk Analysis.
Open Forum Infect Dis
January 2025
Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background: Identifying risk factors for mortality in patients with bacteremia (SAB) is crucial due to its high fatality. However, data on risk factors for infection-attributable deaths considering competing risk events such as non-infection-attributable deaths remain limited. We performed a competing risk analysis to elucidate risk factors associated with 30-day infection-attributable mortality in a large cohort of patients with SAB.
View Article and Find Full Text PDFSkin and Soft Tissue Infection Complicated by Sepsis in an Immunocompromised Patient: A Rare Case Report.
Clin Case Rep
January 2025
Division of Infectious Diseases, Department of Medicine University of Miami Miller School of Medicine Miami Florida USA.
Physicians should consider non-O1, non-O139 (NOVC) in the differential diagnosis of cellulitis complicated by sepsis, especially in immunocompromised patients when potential exposure exists. Due to the pathogen's potential for severe infections and rising incidence from environmental changes, we emphasize the need for increased awareness and appropriate treatment guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!